Tilray's Share Count Keeps Climbing — and That's the Real Story Behind the Rally
Published on 08/05/2026 at 06:41 | Redaktion boerse-global.de
The seven-day winning streak in Tilray Brands' stock tells a story of sector-wide momentum. The company's latest financials tell a more complicated one — where record revenue, shrinking losses, and a sharply rising share count are pulling investors in opposite directions.
Shares closed Tuesday at C$6.39, up 0.79% on the day and roughly 12.5% higher over the past week. The run came amid a broader cannabis-sector rebound, with traders pointing to dealmaking headlines from peers like Vireo Growth as a tailwind. A day earlier, the stock had already jumped 7.64% to C$6.34.
A Record Year, With Caveats
Tilray booked net revenue of US$915.5 million for fiscal 2026, an 11% improvement year over year. Adjusted EBITDA rose by a similar margin. But the headline numbers obscure a persistent problem: the company burned through US$69 million in operating cash flow over the twelve-month period, with another US$56 million consumed by investing activities including acquisitions. Free cash flow landed at negative US$98.6 million, or negative US$86.0 million after adjusting for one-off items.
The beverage segment, often cited as Tilray's diversification play, grew revenue 19% to US$241 million — but much of that came from acquisitions rather than organic demand, making the underlying growth trajectory harder to gauge. In the fourth quarter alone, beverages jumped 61% to US$105.6 million, with US$51.1 million of that coming from the BrewDog brand.
Should investors sell immediately? Or is it worth buying Tilray?
The Dilution Question
The most consequential number in the report may be the share count. Tilray issued US$158.0 million in new equity during fiscal 2026, net of costs, pushing the weighted average share count up 26% to 111.8 million. The pace accelerated in the fourth quarter, with shares outstanding climbing 18% to 115.5 million.
And the pressure isn't letting up. An at-the-market equity program launched in April allows for up to US$180 million in additional issuance. As of July 28, Tilray had already raised US$87 million gross through that facility at an average price of US$6.77 per share.
For existing shareholders, the math is straightforward: each new issuance dilutes their stake further, and with cash burn continuing, analysts expect more of the same.
Balance Sheet Bright Spots
Not everything points to strain. Tilray ended the year with roughly US$234.6 million in cash, restricted funds, and marketable securities. Net debt came in at under US$1 million, down from around US$14 million a year earlier. CFO Carl Merton highlighted roughly US$60 million in debt reduction during and after the fiscal year, including repayments and non-cash conversions of convertible notes.
Still, the company carries US$227 million in liabilities on its balance sheet, plus US$171.5 million in lease obligations. The net debt figure, while low, reflects Tilray's own definition.
The GAAP net loss narrowed to US$105.2 million — a stark improvement only because the prior year was weighed down by US$2.1 billion in impairment charges that didn't recur.
Wall Street Can't Agree
Analyst opinions remain sharply divided. TD Cowen's Derek Lessard reiterated a Buy with a US$5 price target, while ATB's Frederico Gomes and Alliance Global's Aaron Grey both sit at Hold, with targets of US$8 and US$5 respectively. The spread underscores a fundamental disagreement over whether Tilray's transformation from cannabis pure-play to a diversified beverage, hospitality, and wellness company will ultimately create value.
Tilray at a turning point? This analysis reveals what investors need to know now.
Management is leaning into that vision. For fiscal 2027, Tilray guides to adjusted EBITDA between US$68 million and US$75 million, implying 11% to 23% growth. Revenue is expected to cross the US$1 billion mark, though the company hasn't provided a specific range. CEO Irwin Simon framed the strategy in deliberately broad terms, saying the next chapter "will not be defined by a single product, a single market, or a single regulatory event."
The Skeptics' View
The bearish camp isn't buying it. A critical analysis published Tuesday argued there's "no compelling reason to believe the situation will improve," describing the pattern as "the same old story as in previous years." Investors, the argument goes, remain unimpressed by a growth strategy that keeps requiring fresh capital.
Fourth-quarter results did show momentum — revenue rose 25% to US$281.7 million from US$224.5 million a year earlier, with all four segments contributing growth. But the fundamental tension remains: Tilray keeps growing, and keeps needing to sell more shares to fund that growth. Whether the market rewards that trade-off or punishes it will likely define the stock's next chapter.
Ad
Tilray Stock: New Analysis - 5 August
Fresh Tilray information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
